Autonomic Dysfunction Diagnosis: A Comprehensive Guide for Clinicians

Introduction to Autonomic Dysfunction

The autonomic nervous system (ANS) is a critical network within the body that operates largely outside of our conscious control. It governs a vast array of involuntary physiological processes essential for maintaining homeostasis, from regulating blood pressure and heart rate to digestion and body temperature. This intricate system, encompassing the sympathetic, parasympathetic, and enteric branches, ensures our body adapts seamlessly to both internal needs and external demands. When this system malfunctions, it leads to autonomic dysfunction, or dysautonomia, a condition that can significantly impact daily life. This article provides an in-depth exploration of Autonomic Dysfunction Diagnosis, aiming to enhance understanding and improve clinical practice in this complex area.

The ANS is responsible for the rapid, short-term adjustments necessary for survival and interaction with the environment, working alongside the endocrine system’s slower, longer-lasting hormonal controls. Key autonomic functions include:

• Cardiovascular Regulation: Controlling heart rate and blood pressure to ensure whole-body perfusion.
• Thermoregulation: Managing body temperature through sweating and shivering mechanisms.
• Digestion and Nutrient Processing: Coordinating the gut and related glands for efficient nutrient absorption.
• Urinary Function: Regulating bladder motility.
• Ocular Function: Controlling pupil movement, focus, and tear production.

Dysfunction within any part of the ANS can manifest as a wide range of symptoms and, when associated with other underlying conditions, can worsen their prognosis. In severe cases, autonomic dysfunction itself becomes the primary clinical concern, necessitating targeted diagnosis and management.

Autonomic Nervous System Functions

Function	System Component	Examples
Heart Rate Regulation	Sympathetic & Parasympathetic	Increasing heart rate during exercise, slowing heart rate during rest
Blood Pressure Control	Sympathetic & Parasympathetic	Vasoconstriction to raise blood pressure, vasodilation to lower blood pressure
Body Temperature Regulation	Sympathetic	Sweating to cool down, shivering to warm up
Digestion	Parasympathetic & Enteric	Stimulating stomach acid production, controlling intestinal movement
Urinary Motility	Parasympathetic	Bladder contraction for urination
Pupil Control	Sympathetic & Parasympathetic	Pupil dilation in low light, pupil constriction in bright light

Etiology of Autonomic Dysfunction

Autonomic dysfunction is not a single disease but rather a syndrome resulting from various underlying causes. Given the extensive reach of the ANS, numerous conditions can disrupt its function, often with multiple factors contributing in a single patient. Understanding the etiology is crucial for accurate autonomic dysfunction diagnosis and targeted treatment. The causes can be broadly categorized as inherited and acquired.

Inherited Causes

Genetic predispositions play a significant role in certain autonomic disorders:

• Amyloidosis, Fabry disease, hereditary sensory autonomic neuropathy, porphyrias: These are examples of inherited metabolic disorders that can affect the nervous system, including the ANS.
• Familial dysautonomia (Riley-Day syndrome) and dopamine-beta-hydroxylase deficiency: These are specific genetic disorders primarily affecting autonomic function.

Acquired Causes

Acquired autonomic dysfunction is far more common and arises from a wide array of conditions:

• Autoimmune Disorders:
  • Guillain-Barré syndrome: An acute inflammatory polyneuropathy that can affect autonomic nerves.
  • Autoimmune autonomic ganglionopathy (AAG): A condition where the body’s immune system attacks autonomic ganglia.
  • Lambert-Eaton myasthenic syndrome (LEMS): An autoimmune disorder that can affect neuromuscular junctions and autonomic function.
  • Rheumatoid arthritis, Sjögren’s syndrome, systemic lupus erythematosus (SLE): Systemic autoimmune diseases that can have secondary autonomic involvement.
• Reflex Abnormalities:
  • Carotid sinus hypersensitivity, vasovagal syncope, neurocardiogenic syncope: Conditions involving exaggerated autonomic reflexes leading to syncope.
  • Postural orthostatic tachycardia syndrome (POTS): Characterized by excessive heart rate increase upon standing, often linked to autonomic dysregulation.
• Sweating Disorders:
  • Generalized or focal hyperhidrosis: Excessive sweating, indicating autonomic hyperactivity in sweat gland control.
• Metabolic and Nutritional Deficiencies:
  • Diabetes mellitus: A major cause of autonomic neuropathy, particularly diabetic autonomic neuropathy.
  • Vitamin B12 deficiency: Can lead to neurological complications, including autonomic dysfunction.
• Degenerative Neurological Diseases:
  • Parkinson’s disease: Autonomic dysfunction is a common non-motor symptom.
  • Multiple system atrophy (MSA) / Shy-Drager syndrome: A severe neurodegenerative disorder with prominent autonomic failure.
  • Pure autonomic failure (PAF): Primary degeneration of autonomic neurons, leading to orthostatic hypotension and other autonomic symptoms.
• Infections:
  • Botulism, Chagas disease, HIV, leprosy, Lyme disease, tetanus: Infectious agents that can directly or indirectly damage the ANS.
• Neoplasia:
  • Brain tumors, paraneoplastic syndromes: Tumors can affect autonomic pathways directly or indirectly through paraneoplastic effects.
• Pharmacological Effects:
  • Many drugs can interfere with autonomic function, leading to side effects like orthostatic hypotension. Examples include alpha-blockers and beta-blockers.
• Toxins and Drug-Induced Neuropathy:
  • Alcohol, amiodarone, chemotherapy agents: Substances that can cause autonomic neuropathy.
• Traumatic Injuries:
  • Spinal cord injuries: Can disrupt autonomic pathways, leading to autonomic dysreflexia and other autonomic disturbances.
• Uremic Neuropathy and Chronic Liver Diseases: Systemic illnesses that can secondarily affect autonomic nerve function.

Medications That Exacerbate Orthostatic Hypotension

Certain medications are known to worsen orthostatic hypotension, a common symptom of autonomic dysfunction. Clinicians should be aware of these when evaluating patients:

• Diuretics: Furosemide, torsemide, thiazides
• Nitric Oxide Vasodilators: Nitroglycerine, hydralazine, sildenafil
• Adrenergic Antagonists:
  • Alpha-1 Blockers: Alfuzosin, terazosin
  • Beta-Blockers: Propranolol
• Alpha-2 Adrenergic Agonists: Tizanidine, clonidine
• Renin-Angiotensin System Inhibitors: Lisinopril, valsartan
• Dopamine Antagonists:
  • Phenothiazines: Chlorpromazine
  • Atypical Antipsychotics: Olanzapine, risperidone, quetiapine
• Calcium Channel Blockers: Verapamil, diltiazem
• Selective Serotonin Reuptake Inhibitors (SSRIs): Paroxetine
• Antidepressants: Trazodone, amitriptyline

Epidemiology of Autonomic Dysfunction

Autonomic dysfunction is a prevalent condition, though its overall incidence is challenging to quantify due to the diverse manifestations and underlying causes. Cardiovascular autonomic dysfunction, particularly vasovagal syncope, is among the most common presentations. Postural tachycardia syndrome (POTS) and autonomic changes associated with Parkinson’s disease and related disorders are also frequently observed.

Urinary incontinence, while less specific, is a common autonomic symptom in conditions like multiple sclerosis and other neurological disorders. Certain autonomic symptoms, such as facial vasomotor and ocular disturbances in trigeminal autonomic cephalalgias, are diagnostically significant despite being less broadly prevalent.

Orthostatic hypotension increases with age and is more common in institutionalized elderly populations. POTS disproportionately affects women, while syncope is widespread, especially in adolescents and individuals over 55. Reflex syncope is the most common type. Carotid sinus hypersensitivity and syncope related to specific triggers like defecation or cough are more prevalent in older adults.

Pathophysiology of Autonomic Dysfunction

The pathophysiology of autonomic dysfunction varies depending on the specific area and component of the ANS affected. Dysfunction can arise from lesions at various levels, from peripheral nerves to central nervous system structures.

In the cardiovascular system, key pathophysiological syndromes related to chronic autonomic dysfunction include:

• Postural Orthostatic Tachycardia Syndrome (POTS): Characterized by excessive tachycardia upon standing without hypotension.
• Orthostatic Hypotension with Supine Hypertension: Low blood pressure upon standing, paradoxically accompanied by high blood pressure when lying down.
• Reflex Cardiovascular Syndromes: Including vasovagal syncope, carotid sinus syncope, and situational syncope.

Thermoregulatory dysfunction manifests as hyperhidrosis (excessive sweating) or hypohidrosis (reduced sweating). Ocular autonomic dysfunction can present as fixed mydriasis (dilated pupils), myosis (constricted pupils), Adie’s pupil, or Horner syndrome.

Autonomic dysfunction can stem from diseases affecting either the peripheral or central nervous system. Primary autonomic dysfunction involves idiopathic degeneration of autonomic postganglionic fibers without other neurological abnormalities, as seen in pure autonomic failure. In contrast, autonomic dysfunction associated with motor and cerebellar deficits, such as in multiple system atrophy (Shy-Drager syndrome), indicates a central degenerative process. Parkinsonian symptoms combined with orthostatic hypotension may suggest central preganglionic neuronal degeneration.

Orthostatic hypotension is physiologically defined as a sustained decrease in systolic blood pressure by at least 20 mmHg or diastolic blood pressure by 10 mmHg within three minutes of standing or head-up tilt (at least 60 degrees). The extent of blood pressure drop is influenced by baseline blood pressure; in individuals with supine hypertension, a systolic drop of 30 mmHg might be more appropriate criteria. Upon standing, blood pooling in the lower limbs (300-800 ml) reduces venous return and cardiac filling pressure. Normally, skeletal muscle contraction in the legs counteracts pooling and enhances venous return. Orthostatic hypotension arises from either insufficient cardiac output or impaired vasoconstriction.

Neurally mediated (reflex) syncope, encompassing vasovagal, carotid sinus, and situational syncope, results from sudden shifts in ANS activity causing drops in blood pressure, heart rate, and cerebral perfusion. It is best understood as a reflex arc with afferent, central, and efferent pathways. The term ‘neurocardiogenic syncope’ is less accurate as the reflex origin is rarely cardiac.

Postural tachycardia syndrome (POTS) is defined by a sustained heart rate increase of 30 bpm or more within 10 minutes of standing (40 bpm in adolescents aged 12-19), without orthostatic hypotension. POTS symptoms include autonomic overactivity and cerebral hypoperfusion, relieved by lying down. The exact causes of POTS are likely heterogeneous and may involve prior viral illnesses, chronic fatigue syndrome, deconditioning, and limited autonomic neuropathy.

Diabetic neuropathy, a complication of diabetes mellitus, impairs nerve signaling and damages blood vessels (vasa nervorum) supplying nerves. Diabetic autonomic neuropathy often affects general visceral afferent (GVA) fibers, leading to gastroparesis and blood pressure dysregulation. GVA fiber dysfunction reduces the corresponding general visceral efferent (GVE) responses.

Parkinson’s disease, a progressive neurodegenerative disorder, is characterized by motor symptoms (bradykinesia, tremor, rigidity) and common non-motor autonomic symptoms like constipation, dysphagia, sialorrhea, rhinorrhea, urinary issues, and sexual dysfunction. These autonomic features also occur in multiple system atrophy (MSA), making differentiation challenging. However, autonomic symptoms in MSA are typically more severe, and MSA tends to be less responsive to levodopa and often presents with cerebellar and pyramidal signs.

History and Physical Examination in Autonomic Dysfunction Diagnosis

A thorough clinical history, focusing on symptom details in different autonomic domains, is crucial for guiding autonomic dysfunction diagnosis. Emphasis should be placed on cardiovascular, urinary, neurological, and sudomotor manifestations. Orthostatic syncope or presyncope should raise immediate suspicion of cardiovascular autonomic dysfunction. Typical orthostatic symptoms include:

• Lightheadedness
• Visual blurring or tunnel vision
• Neck pain (coat-hanger pain)
• Nausea
• Palpitations
• Tremulousness
• Weakness
• Dizziness

Other associated symptoms can include exercise intolerance, fatigue, shortness of breath, chest pain, anxiety, hyperventilation, acral coldness or pain, concentration difficulties, and headaches. Altered sweating patterns, such as distal hypohidrosis sparing palms and soles, may indicate a sudomotor autonomic lesion. Urinary urgency and incontinence are more suggestive of neurogenic bladder than urinary retention.

Evaluation and Diagnostic Testing for Autonomic Dysfunction

Objective testing is often necessary to confirm autonomic dysfunction diagnosis and to provide evidence for treatment decisions. Bedside evaluation of the ANS involves assessing cardiovascular reflexes, sweating patterns, and pupillary responses.

Bedside Autonomic Function Tests

• Orthostatic Blood Pressure Measurement: Measuring blood pressure and heart rate in supine and standing positions (after 3 minutes) is the most common initial test.
• Heart Rate Variability Assessment: Evaluating heart rate changes during deep breathing or Valsalva maneuver can provide insights into autonomic cardiac control.

Advanced Autonomic Function Tests

When bedside tests are inconclusive but autonomic dysfunction is still suspected, more specialized tests are warranted:

• Tilt Table Test: Evaluates cardiovascular responses to postural change, often incorporating stimuli like Valsalva maneuver, hyperventilation, or cold pressor test.
• Sympathetic Skin Response (SSR): Measures sweat gland activity in response to stimulation, assessing sympathetic sudomotor function.
• Thermoregulatory Sweat Test (TST): Maps sweating patterns across the body to identify areas of hypohidrosis or hyperhidrosis, useful when sweating abnormalities are prominent.
• Vesical Ultrasonography and Urodynamic Studies: Assess bladder function and are helpful in diagnosing neurogenic bladder contributing to urinary dysfunction.
• Pupillometry and Pharmacological Pupil Testing: Quantitative pupillometry measures pupil size and reactivity. Pharmacological testing with eye drops (e.g., pilocarpine, cocaine, apraclonidine) can help localize pupillary abnormalities (e.g., Horner’s syndrome, Adie’s pupil).
• Autoantibody Testing: In cases of suspected autoimmune autonomic ganglionopathy, testing for autoantibodies against ganglionic acetylcholine receptors can support immunosuppressive therapy decisions.

Tilt Table Test Indications and Responses

Indications for Tilt Table Test:

• Unexplained syncope or presyncope
• Orthostatic intolerance symptoms
• Suspected vasovagal syncope or POTS
• Evaluation of treatment response in orthostatic hypotension

Normal Responses to Head-Up Tilt-Table Testing:

Normal Tilt Table Test Responses

Parameter	Normal Response
Heart Rate	Increases by 10 to 15 beats per minute
Diastolic Blood Pressure	Increases by 10 mm Hg or more
Systolic Blood Pressure	May slightly increase or remain relatively stable

Treatment and Management of Autonomic Dysfunction

Autonomic dysfunction management is multifaceted, addressing symptom relief, underlying pathophysiology, and etiology. Treatment strategies are organized into three levels:

1. Symptom Management: The primary focus is often on alleviating the most bothersome symptoms. Non-pharmacological and pharmacological measures are used. Physical measures such as exercise, tailored physiotherapy, and compression stockings can aid cardiovascular autonomic dysfunction. Sunglasses can help with mydriasis-related light sensitivity.

2. Pathophysiological Treatment: In immune-mediated autonomic disorders, immunotherapy, including corticosteroids, immunosuppressants, intravenous immunoglobulins (IVIG), and plasma exchange, can be employed to target the underlying autoimmune process.

3. Etiological Treatment: Addressing the root cause is crucial. This may involve treating underlying malignancies in paraneoplastic syndromes or managing infections. For drug-induced autonomic dysfunction, medication withdrawal or dose adjustment is essential.

Management of Orthostatic Hypotension

Non-Pharmacological Measures:

• Discontinue Exacerbating Medications: Review and, if possible, stop medications that worsen orthostatic hypotension.
• Compression Stockings and Abdominal Binders: Help reduce blood pooling in the lower body.
• Increase Salt and Water Intake: Drinking 500 mL of water upon waking and aiming for 1.5 to 3 L daily is recommended. Salt intake should be increased to 6-10 g/day, or target urinary sodium excretion of 150-200 mEq/day.
• Lifestyle Modifications: Change postures slowly, avoid Valsalva maneuvers, limit exposure to hot and humid environments, and minimize hot showers/saunas.
• Exercise Programs: Engage in exercise in sitting or recumbent positions to improve orthostatic tolerance.

Pharmacotherapy:

Pharmacological treatment is indicated when non-pharmacological measures are insufficient. FDA-approved medications for neurogenic orthostatic hypotension include:

1. Midodrine: An alpha-adrenergic agonist that increases vasoconstriction.
2. Droxidopa: A norepinephrine precursor that increases norepinephrine levels, enhancing vasoconstriction.

Fludrocortisone, a mineralocorticoid, is also commonly used to expand intravascular volume, although not specifically FDA-approved for neurogenic orthostatic hypotension and can cause supine hypertension and other side effects.

For patients unresponsive to initial measures, supine norepinephrine levels should be assessed. Low levels may indicate norepinephrine deficiency and guide further treatment.

Adjunctive or Alternative Therapies:

• Caffeine
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Pyridostigmine
• Erythropoietin
• Experimental agents: yohimbine, desmopressin, dihydroergotamine, metoclopramide, norepinephrine infusion (evidence for these is limited).

Management of Autonomic Dysfunction in Parkinson’s Disease

• Constipation: Polyethylene glycol, probiotics, and lubiprostone are effective treatments.
• Sialorrhea (Drooling): Hard candy or chewing gum for mild symptoms. Botulinum toxin injections into salivary glands or glycopyrrolate for severe cases.
• Rhinorrhea: Ipratropium nasal spray (anticholinergic).
• Sexual Dysfunction:
  • Men: Sildenafil, tadalafil, or vardenafil for erectile dysfunction (caution with orthostatic hypotension).
  • Women: Vaginal lubricants and voiding before intercourse.
• Orthostatic Hypotension: Manage as described above, considering Parkinson’s medications may contribute.

Differential Diagnosis of Orthostatic Hypotension

Orthostatic hypotension is a symptom with a broad differential diagnosis, encompassing cardiovascular, pharmacological, endocrine, and other conditions:

• Cardiovascular: Anemia, cardiac arrhythmia, congestive heart failure, myocardial infarction, myocarditis, pericarditis, valvular heart disease, venous insufficiency.
• Drugs: Alcohol, antiadrenergic medications, antianginals, antiarrhythmics, antidepressants, antihypertensives, antiparkinsonian agents, diuretics, narcotics, neuroleptics, sedatives.
• Endocrine: Adrenal insufficiency, diabetes insipidus, hypoaldosteronism, hyperglycemia, hypokalemia, hypothyroidism.
• Intravascular Volume Depletion: Blood loss, dehydration, shock, pregnancy/postpartum.
• Miscellaneous: AIDS, anxiety, panic disorder, eating disorders, prolonged bed rest.

Prognosis of Autonomic Dysfunction

The prognosis of autonomic dysfunction is highly variable. Secondary autonomic dysfunction prognosis is primarily determined by the underlying disease. Primary autonomic disorders, especially those associated with parkinsonian features or movement disorders, generally have a poorer prognosis. The onset of primary autonomic syndromes typically occurs in the sixth decade, with a five-year survival rate of less than 50% after neurological symptom onset.

Complications of Autonomic Dysfunction

Orthostatic hypotension, particularly when symptomatic, significantly increases the risk of falls, especially in the elderly, leading to fractures and other injuries. It is also a risk factor for cardiovascular and all-cause mortality, often due to associated underlying diseases. Orthostatic hypotension has been linked to an increased risk of dementia and cognitive impairment, possibly due to recurrent cerebral hypoperfusion and vascular damage. It may also be a prodromal symptom of neurodegenerative conditions like dementia with Lewy bodies.

Clinical Pearls and Key Considerations in Autonomic Dysfunction Diagnosis

Autonomic dysfunction remains underdiagnosed and undertreated in many healthcare settings. Diagnosis is often delayed until symptoms become chronic and severe. Increased awareness within the medical community, improved diagnostic tools, and the development of more effective and validated therapies are crucial areas for future research and clinical progress.

Autonomic dysreflexia is a critical, potentially life-threatening condition, particularly in patients with spinal cord injuries. It can be triggered by various stimuli, from pain to bowel or bladder issues, and can lead to severe hypertension, cardiac ischemia, stroke, seizures, and death. Clinicians must maintain vigilance for autonomic dysreflexia in at-risk patients.

Enhancing Healthcare Team Outcomes in Autonomic Dysfunction Management

Optimal management of autonomic dysfunction requires an interprofessional team approach. Specialists such as neurologists, endocrinologists, internists, urologists, and cardiologists are often needed. Treatment is primarily symptomatic and frequently involves medications with potential side effects. Autonomic dysfunction can significantly impair quality of life, emphasizing the need for coordinated and comprehensive care.

Review Questions

(Note: Review questions would typically be included in the original article format but are omitted here as per instructions.)

References

(References are listed as in the original article)

1.Waxenbaum JA, Reddy V, Varacallo MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 24, 2023. Anatomy, Autonomic Nervous System. [PubMed: 30969667]
2.Sternini C. Organization of the peripheral nervous system: autonomic and sensory ganglia. J Investig Dermatol Symp Proc. 1997 Aug;2(1):1-7. [PubMed: 9487007]
3.Karemaker JM. An introduction into autonomic nervous function. Physiol Meas. 2017 May;38(5):R89-R118. [PubMed: 28304283]
4.Lake JI, Heuckeroth RO. Enteric nervous system development: migration, differentiation, and disease. Am J Physiol Gastrointest Liver Physiol. 2013 Jul 01;305(1):G1-24. [PMC free article: PMC3725693] [PubMed: 23639815]
5.Siéssere S, Vitti M, Sousa LG, Semprini M, Iyomasa MM, Regalo SC. Anatomic variation of cranial parasympathetic ganglia. Braz Oral Res. 2008 Apr-Jun;22(2):101-5. [PubMed: 18622477]
6.Ziemssen T, Siepmann T. The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review. Front Neurol. 2019;10:53. [PMC free article: PMC6380109] [PubMed: 30809183]
7.Hong CT, Chan L, Wu D, Chen WT, Chien LN. Association Between Parkinson’s Disease and Atrial Fibrillation: A Population-Based Study. Front Neurol. 2019;10:22. [PMC free article: PMC6370731] [PubMed: 30804869]
8.James LA, Levin MA, Lin HM, Deiner SG. Association of Preoperative Frailty With Intraoperative Hemodynamic Instability and Postoperative Mortality. Anesth Analg. 2019 Jun;128(6):1279-1285. [PubMed: 31094800]
9.Chung SJ, Bae YJ, Jun S, Yoo HS, Kim SW, Lee YH, Sohn YH, Lee SK, Seong JK, Lee PH. Dysautonomia is associated with structural and functional alterations in Parkinson disease. Neurology. 2019 Mar 26;92(13):e1456-e1467. [PubMed: 30796135]
10.Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019 Feb;43(1):3-30. [PMC free article: PMC6387879] [PubMed: 30793549]
11.Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, Biaggioni I, Robertson D. Dysautonomia: perioperative implications. Anesthesiology. 2012 Jan;116(1):205-15. [PMC free article: PMC3296831] [PubMed: 22143168]
12.McLeod JG. Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):274-83. [PMC free article: PMC1073360] [PubMed: 7897405]
13.Ludwig PE, Reddy V, Varacallo MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 10, 2022. Neuroanatomy, Central Nervous System (CNS) [PubMed: 28723039]
14.Barboza CA, Fukushima AR, Carrozzi N, Machi JF, Dourado PMM, Mostarda CT, Irigoyen MC, Nathanson L, Morris M, Caperuto EC, Rodrigues B. Cholinergic Stimulation by Pyridostigmine Bromide Before Myocardial Infarction Prevent Cardiac and Autonomic Dysfunction. Sci Rep. 2019 Feb 21;9(1):2481. [PMC free article: PMC6385301] [PubMed: 30792425]
15.Nattero-Chávez L, Redondo López S, Alonso Díaz S, Garnica Ureña M, Fernández-Durán E, Escobar-Morreale HF, Luque-Ramírez M. Association of Cardiovascular Autonomic Dysfunction With Peripheral Arterial Stiffness in Patients With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Jul 01;104(7):2675-2684. [PubMed: 30786000]
16.Traunmüller C, Stefitz R, Gaisbachgrabner K, Hofmann P, Roessler A, Schwerdtfeger AR. Psychophysiological concomitants of burnout: Evidence for different subtypes. J Psychosom Res. 2019 Mar;118:41-48. [PubMed: 30782353]
17.Allen DR, Huang MU, Morris NB, Chaseling GK, Frohman EM, Jay O, Davis SL. Impaired Thermoregulatory Function during Dynamic Exercise in Multiple Sclerosis. Med Sci Sports Exerc. 2019 Mar;51(3):395-404. [PubMed: 30779715]
18.Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. [PubMed: 21431947]
19.Barbato AL. Bedside Evaluation of the Autonomic System. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Butterworths; Boston: 1990. [PubMed: 21250243]
20.Rathmann W, Enck P, Frieling T, Gries FA. Visceral afferent neuropathy in diabetic gastroparesis. Diabetes Care. 1991 Nov;14(11):1086-9. [PubMed: 1797493]
21.Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007 Jul 24;69(4):333-41. [PubMed: 17646625]
22.Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):674-80. [PubMed: 22942216]
23.Kadoya M, Koyama H. Sleep, Autonomic Nervous Function and Atherosclerosis. Int J Mol Sci. 2019 Feb 13;20(4) [PMC free article: PMC6412503] [PubMed: 30781734]
24.Baschieri F, Cortelli P. Circadian rhythms of cardiovascular autonomic function: Physiology and clinical implications in neurodegenerative diseases. Auton Neurosci. 2019 Mar;217:91-101. [PubMed: 30744907]
25.Bellon G, Venturin A, Masiero S, Del Felice A. Intra-articular botulinum toxin injection in complex regional pain syndrome: Case report and review of the literature. Toxicon. 2019 Mar 01;159:41-44. [PubMed: 30660558]
26.Lanier JB, Mote MB, Clay EC. Evaluation and management of orthostatic hypotension. Am Fam Physician. 2011 Sep 01;84(5):527-36. [PubMed: 21888303]
27.Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006 Sep;13(9):930-6. [PubMed: 16930356]
28.Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007 Oct;120(10):841-7. [PubMed: 17904451]
29.Lamarre-Cliche M, Cusson J. The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance. CMAJ. 2001 Feb 06;164(3):372-6. [PMC free article: PMC80733] [PubMed: 11232140]
30.Nwazue VC, Raj SR. Confounders of vasovagal syncope: orthostatic hypotension. Cardiol Clin. 2013 Feb;31(1):89-100. [PMC free article: PMC3589989] [PubMed: 23217690]
31.Fedorowski A, Melander O. Syndromes of orthostatic intolerance: a hidden danger. J Intern Med. 2013 Apr;273(4):322-35. [PubMed: 23216860]
32.Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich). 2013 Mar;15(3):147-53. [PMC free article: PMC8033893] [PubMed: 23458585]
33.Raj SR, Coffin ST. Medical therapy and physical maneuvers in the treatment of the vasovagal syncope and orthostatic hypotension. Prog Cardiovasc Dis. 2013 Jan-Feb;55(4):425-33. [PMC free article: PMC3594734] [PubMed: 23472781]
34.Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017 May 12;17(1):90. [PMC free article: PMC5427571] [PubMed: 28494751]
35.Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018 Oct 16;91(16):e1539-e1544. [PMC free article: PMC6202942] [PubMed: 30232253]
36.Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C., the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-198. [PMC free article: PMC6916382] [PubMed: 30653247]
37.Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2011 Jan;17(1):10-5. [PubMed: 20829091]
38.Cloud LJ, Greene JG. Gastrointestinal features of Parkinson’s disease. Curr Neurol Neurosci Rep. 2011 Aug;11(4):379-84. [PubMed: 21499704]
39.Thomsen TR, Galpern WR, Asante A, Arenovich T, Fox SH. Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord. 2007 Nov 15;22(15):2268-73. [PubMed: 17876852]
40.Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur Urol. 2002 Apr;41(4):382-6. [PubMed: 12074807]
41.Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003 Dec 15;68(12):2393-8. [PubMed: 14705758]
42.van Hateren KJ, Kleefstra N, Blanker MH, Ubink-Veltmaat LJ, Groenier KH, Houweling ST, Kamper AM, van der Meer K, Bilo HJ. Orthostatic hypotension, diabetes, and falling in older patients: a cross-sectional study. Br J Gen Pract. 2012 Oct;62(603):e696-702. [PMC free article: PMC3459777] [PubMed: 23265229]
43.Gangavati A, Hajjar I, Quach L, Jones RN, Kiely DK, Gagnon P, Lipsitz LA. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011 Mar;59(3):383-9. [PMC free article: PMC3306056] [PubMed: 21391928]
44.Luukinen H, Koski K, Laippala P, Airaksinen KE. Orthostatic hypotension and the risk of myocardial infarction in the home-dwelling elderly. J Intern Med. 2004 Apr;255(4):486-93. [PubMed: 15049883]
45.Kruit MC, Thijs RD, Ferrari MD, Launer LJ, van Buchem MA, van Dijk JG. Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology. 2013 May 21;80(21):1958-65. [PMC free article: PMC3716345] [PubMed: 23616159]
46.Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, Low PA, Singer W, Goldstein DS, Peltier AC, Shibao CA, Gibbons CH, Freeman R, Robertson D., Autonomic Disorders Consortium. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol. 2017 Feb;81(2):287-297. [PMC free article: PMC5323269] [PubMed: 28093795]
47.Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Doumas M, Papadopoulos D, Tousoulis D. Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. J Clin Hypertens (Greenwich). 2019 Mar;21(3):426-433. [PMC free article: PMC8030346] [PubMed: 30724451]
48.Grisanti LA. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front Physiol. 2018;9:1669. [PMC free article: PMC6275303] [PubMed: 30534081]